Zobrazit v EDS

Pattern and Distribution of Skeletal Metastases in Patients With Prostate Cancer in Ghana: A Descriptive Analysis and a Model-Based Digital Nomogram for Oligo-Ostotic Versus Polyostotic Metastases.

Uloženo v:
Podrobná bibliografie
Název: Pattern and Distribution of Skeletal Metastases in Patients With Prostate Cancer in Ghana: A Descriptive Analysis and a Model-Based Digital Nomogram for Oligo-Ostotic Versus Polyostotic Metastases.
Autoři: Obeng, Frank, Korsah, Clement, Fadil, Mohammed, Agbeteti, Godson, Amenyo, Obed K, Okai, Eric N, Seshie, Daniel S, Owusu Boateng, Jephtha, Dzomeku, Justice, Hammond, Nii-Boye
Zdroj: Cureus: Journal of Medical Science; Aug2025, Vol. 17 Issue 8, p1-27, 27p
Témata: PROSTATE cancer, BONE metastasis, SPATIAL analysis (Statistics), NOMOGRAPHY (Mathematics), RESOURCE-limited settings
Geografický termín: GHANA
Abstrakt: Background: Bone involvement is a frequent and serious consequence of advanced prostate cancer. Understanding the distribution and pattern of bone involvement is essential for early detection, staging, and appropriate therapeutic intervention, particularly in low-resource settings where late presentation is frequent. Objective: To characterize the anatomical distribution and burden of skeletal metastases in a cohort of newly diagnosed patients with prostate cancer with bone involvement. Methods: A one-year cross-sectional review of bone scans from 100 newly diagnosed patients with prostate cancer with confirmed skeletal metastases was conducted. Standardized site coding produced frequency tables, total/per-patient counts, and descriptive statistics (mean, median, mode, and IQR). Axial vs. appendicular patterns were shown with bar charts and skeletal heatmaps. A logistic regression model-girded digital nomogram (derived, validated, tested, and updated) predicted superscan/polyostotic metastasis risk. Analyses were in Stata Version 17 (StataCorp LLC, College Station, TX) and Python (Python Software Foundation, Fredericksburg, VA) at α = 0.05. Results: A total of 470 bone metastatic sites were documented among 100 newly diagnosed patients with prostate cancer, aged 51 to 89 (mean age = 68.81, mode = 65, SD = 7.07 years) with a mean prostate-specific antigen (PSA) of 924.32 ng/ml (range = 5.76 to 2223, SD = 2656.47 ng/ml), alkaline phosphatase (ALP), mean = 239.43, range = 45 to 3265, SD = 438.57, digital rectal examination (DRE) risk (median = 3, IQR = 1), International Society of Urological Pathology (ISUP) risk (median = 3, IQR = 1), and D'Amico risk categories (median = 3, IQR = 0). The number of metastases per patient ranged from 1 to 19, with a mean of 4.7 sites (SD = 2.98), a median of 5 (IQR: 3-7), and a mode of 3. Across the 15 anatomic sites identified, the lesion per-anatomic site per-patient (mean, median, mode, and SD) were 0.31, 1.0, 3.0, and 2.55, respectively. There was notable variability in metastatic burden (solitary lesions in 33.0%, three or more lesions in 51.0%, and superscan/polyostotic lesions (> 4 metastatic sites) in 33.0%), also suggesting heavy burden disease amongst the cohort. The most commonly involved sites were the spine (32.6%), ribs (25.7%), and pelvis (16.1%), the skull (5.2%), and hand and foot bones had zero metastasis. The axial skeleton accounted for 68.1% of all metastatic deposits, and this centripetal spread was further highlighted by heatmap visualizations. Phenotypic clustering revealed that a patient with PSA > 100 ng/ml but moderate ALP (62-122 U/L) is most likely to fall in Q1 (oligo-metastatic pattern; likelihood-ratio (LR) = 31.33 (df = 4), p < 0.0001). Conversely, the combination of age (55-75 years), PSA > 100 ng/ml, and ALP ≥ 222 U/L sharply elevates the likelihood of Q3 (polyostotic disease), regardless of already-high clinical risk scores (LR = 29.77 (df = 4), p < 0.0001). A logistic regression model-girded digital nomogram for oligo-ostotic versus polyostotic metastatic prostate cancer was derived, validated, trained, and deployed, achieving an area under the curve (AUC) of 81.0% at the end. Conclusion: Axial skeletal metastasis dominates in prostate cancer bone metastasis. Heavy burden metastasis was rampant. These findings emphasize the need for early diagnostic strategies and risk-adapted imaging protocols to improve outcomes in resource-limited settings. [ABSTRACT FROM AUTHOR]
Copyright of Cureus: Journal of Medical Science is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Databáze: Complementary Index
Popis
Abstrakt:Background: Bone involvement is a frequent and serious consequence of advanced prostate cancer. Understanding the distribution and pattern of bone involvement is essential for early detection, staging, and appropriate therapeutic intervention, particularly in low-resource settings where late presentation is frequent. Objective: To characterize the anatomical distribution and burden of skeletal metastases in a cohort of newly diagnosed patients with prostate cancer with bone involvement. Methods: A one-year cross-sectional review of bone scans from 100 newly diagnosed patients with prostate cancer with confirmed skeletal metastases was conducted. Standardized site coding produced frequency tables, total/per-patient counts, and descriptive statistics (mean, median, mode, and IQR). Axial vs. appendicular patterns were shown with bar charts and skeletal heatmaps. A logistic regression model-girded digital nomogram (derived, validated, tested, and updated) predicted superscan/polyostotic metastasis risk. Analyses were in Stata Version 17 (StataCorp LLC, College Station, TX) and Python (Python Software Foundation, Fredericksburg, VA) at α = 0.05. Results: A total of 470 bone metastatic sites were documented among 100 newly diagnosed patients with prostate cancer, aged 51 to 89 (mean age = 68.81, mode = 65, SD = 7.07 years) with a mean prostate-specific antigen (PSA) of 924.32 ng/ml (range = 5.76 to 2223, SD = 2656.47 ng/ml), alkaline phosphatase (ALP), mean = 239.43, range = 45 to 3265, SD = 438.57, digital rectal examination (DRE) risk (median = 3, IQR = 1), International Society of Urological Pathology (ISUP) risk (median = 3, IQR = 1), and D'Amico risk categories (median = 3, IQR = 0). The number of metastases per patient ranged from 1 to 19, with a mean of 4.7 sites (SD = 2.98), a median of 5 (IQR: 3-7), and a mode of 3. Across the 15 anatomic sites identified, the lesion per-anatomic site per-patient (mean, median, mode, and SD) were 0.31, 1.0, 3.0, and 2.55, respectively. There was notable variability in metastatic burden (solitary lesions in 33.0%, three or more lesions in 51.0%, and superscan/polyostotic lesions (> 4 metastatic sites) in 33.0%), also suggesting heavy burden disease amongst the cohort. The most commonly involved sites were the spine (32.6%), ribs (25.7%), and pelvis (16.1%), the skull (5.2%), and hand and foot bones had zero metastasis. The axial skeleton accounted for 68.1% of all metastatic deposits, and this centripetal spread was further highlighted by heatmap visualizations. Phenotypic clustering revealed that a patient with PSA > 100 ng/ml but moderate ALP (62-122 U/L) is most likely to fall in Q1 (oligo-metastatic pattern; likelihood-ratio (LR) = 31.33 (df = 4), p < 0.0001). Conversely, the combination of age (55-75 years), PSA > 100 ng/ml, and ALP ≥ 222 U/L sharply elevates the likelihood of Q3 (polyostotic disease), regardless of already-high clinical risk scores (LR = 29.77 (df = 4), p < 0.0001). A logistic regression model-girded digital nomogram for oligo-ostotic versus polyostotic metastatic prostate cancer was derived, validated, trained, and deployed, achieving an area under the curve (AUC) of 81.0% at the end. Conclusion: Axial skeletal metastasis dominates in prostate cancer bone metastasis. Heavy burden metastasis was rampant. These findings emphasize the need for early diagnostic strategies and risk-adapted imaging protocols to improve outcomes in resource-limited settings. [ABSTRACT FROM AUTHOR]
ISSN:21688184
DOI:10.7759/cureus.91287